Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 80Cr 72Cr 67Cr 60Cr 113.96Cr 7.54TCr 117.97Cr 805.11Cr 319.24Cr 4.03TCr 300.07Cr 293.7Cr 13TCr P/E 2026 *
3.71x
P/E 2027 * 3.55x
Enterprise Value 80Cr 72Cr 67Cr 60Cr 113.96Cr 7.54TCr 117.97Cr 805.11Cr 319.24Cr 4.03TCr 300.07Cr 293.7Cr 13TCr EV / Sales 2026 *
1.62x
EV / Sales 2027 * 1.59x
Free-Float
96.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week+10.02%
Current month+38.00%
1 month+34.54%
3 months+18.38%
6 months+31.25%
Current year+43.32%
1 week 4.34
Extreme 4.345
5
1 month 3.38
Extreme 3.38
5
Current year 2.95
Extreme 2.95
5.78
1 year 2.95
Extreme 2.95
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Free

Director

3,694 0.0022%
20/07/26 Free

Chief Technology Officer

1,37,036 0.0832%
07/07/26 Sell

Chief Financial Officer

-1,27,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+10.02%+43.32%-48.56% 80Cr
+1.26%+6.61%+41.12%+135.59% 1,28600Cr
+0.79%+3.45%+46.35%+93.56% 69TCr
+0.20%+1.28%+27.01%+112.80% 52TCr
-0.44%+3.69%+39.60%+69.51% 39TCr
+0.55%+0.70%+59.00%+44.20% 36TCr
-0.12%+0.74%+26.78%+58.43% 30TCr
+0.37%+0.37%+3.62%+36.44% 29TCr
-0.30%+1.14%+38.59%+74.61% 25TCr
+0.08%+0.71%+34.25%+124.32% 21TCr
Average +0.20%+3.90%+35.96%+70.09% 43TCr
Weighted average by Cap. +0.54%+3.26%+37.63%+96.20%

Financials

2026 *2027 *
Net sales 49Cr 45Cr 41Cr 37Cr 70Cr 4.65TCr 73Cr 497.03Cr 197.08Cr 2.49TCr 185.25Cr 181.32Cr 7.89TCr 50Cr 46Cr 42Cr 38Cr 72Cr 4.75TCr 74Cr 507.7Cr 201.31Cr 2.54TCr 189.22Cr 185.21Cr 8.06TCr
Net income 22Cr 20Cr 18Cr 16Cr 31Cr 2.05TCr 32Cr 218.56Cr 87Cr 1.09TCr 81Cr 80Cr 3.47TCr 24Cr 21Cr 20Cr 18Cr 34Cr 2.23TCr 35Cr 237.86Cr 94Cr 1.19TCr 89Cr 87Cr 3.78TCr
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
13/26/13 $4.830 -0.41% 28,08,074
12/26/12 $4.850 -0.41% 35,68,998
11/26/11 $4.870 +1.25% 28,21,048
10/26/10 $4.810 +2.78% 45,94,417
09/26/09 $4.680 +6.61% 53,31,411
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.830USD
Average target price
6.175USD
Spread / Average Target
+27.85%
  1. Stock Market
  2. Stocks
  3. IRWD Stock